홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /반응

Acetone → 2-[2-(Trifluoromethyl)-6-({4-[1-(trifluoromethyl)cyclopropyl]phenyl}sulfonyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-8-yl]propan-2-ol

HRID 1691464
인쇄

반응식

HRID 1691464 반응식
IC1[CH:3]=[CH:4][C:5]2[NH:11][C:10]3[N:12]=[C:13]([C:16]([F:19])([F:18])[F:17])[CH:14]=[CH:15][C:9]=3[CH2:8][N:7]([S:20]([C:23]3[CH:28]=[CH:27][C:26]([C:29]4([C:32]([F:35])([F:34])[F:33])[CH2:31][CH2:30]4)=[CH:25][CH:24]=3)(=[O:22])=[O:21])[C:6]=2[CH:36]=1.[CH:37]([Mg]Br)(C)C.[CH3:42][C:43]([CH3:45])=[O:44]>C1COCC1.CCOCC>[F:18][C:16]([F:17])([F:19])[C:13]1[CH:14]=[CH:15][C:9]2[CH2:8][N:7]([S:20]([C:23]3[CH:24]=[CH:25][C:26]([C:29]4([C:32]([F:35])([F:34])[F:33])[CH2:31][CH2:30]4)=[CH:27][CH:28]=3)(=[O:21])=[O:22])[C:6]3[CH:36]=[C:42]([C:43]([OH:44])([CH3:37])[CH3:45])[CH:3]=[CH:4][C:5]=3[NH:11][C:10]=2[N:12]=1
참가 물질반응 조건실험 절차후처리출처 및 근거반응 노트

참가 물질

6

반응물 3

HCID 180AcetoneHCID 866490398-Iodo-2-(trifluoromethyl)-6-({4-[1-(trifluoromethyl)cyclopropyl]phenyl}sulfonyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine2회HCID 178418365HCID 178418365, 화합물

생성물 1

HCID 596187832-[2-(Trifluoromethyl)-6-({4-[1-(trifluoromethyl)cyclopropyl]phenyl}sulfonyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-8-yl]propan-2-ol

시약·촉매·용매 2

HCID 3283
Diethyl Ether
용매
HCID 8028Tetrahydrofuran용매

반응 조건

온도
0 °C

실험 절차

To a solution of 8-iodo-2-(trifluoromethyl)-6-({4-[1-(trifluoromethyl)-cyclopropyl]phenyl}sulfonyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine (intermediate 59, 150 mg, 0.235 mmol) in THF (1.5 mL) at 0° C. was added isopropylmagnesium bromide (1.89 mmol of a 2M solution in ether). After stirred at 0° C. for 40 min, acetone (204 mg, 3.52 mmol) was added dropwise and the reaction mixture was gradually brought to rt. The reaction was quenched with saturated aqueous NH4Cl and diluted with EtOAc. The organic layer was separated and the aqueous phase was extracted with EtOAc. The combined extracts were washed with water, brine, dried over MgSO4 and concentrated. Purification of the residue via SiO2 column chromatography provided the title compound. LC/MS: m/e 572.0 (M+H)+. 1H NMR (500 MHz, CDCl3): δ 7.65 (1H, d, J=2.1 Hz), 7.56 (1H, d, J=7.5 Hz), 7.44 (1H, dd, J=8.5, 1.6 Hz), 7.21 (2H, d, J=8.3 Hz), 7.05 (1H, d, J=7.3 Hz), 7.02 (2H, d, J=8.5 Hz), 6.77 (1H, s), 6.74 (1H, J=8.2 Hz), 4.70-4.90 (2H, s, br), 1.64 (6H, s), 1.35-1.42 (4H, m), 1.26-1.30 (4H, m).

후처리

  1. customwas gradually brought to rt
  2. customThe reaction was quenched with saturated aqueous NH4Cl
  3. additiondiluted with EtOAc
  4. customThe organic layer was separated
  5. extractionthe aqueous phase was extracted with EtOAc
  6. washThe combined extracts were washed with water, brine
  7. dry with materialdried over MgSO4
  8. concentrationconcentrated
  9. customPurification of the residue via SiO2 column chromatography

출처 및 근거

ORD 기록
ord-ad1f970cf627463082f9225133935bdf
출처 데이터셋
uspto-grants-2012_04
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US08153626B2

반응 노트

이 페이지에서참가 물질반응 조건실험 절차후처리출처 및 근거반응 노트